Tuesday, December 01, 2020 5:13:12 AM
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=158115031
The Company’s strategic manufacturing facility enables low production costs without compromising quality. SHMN develops, manufactures and markets generic pharmaceuticals in various dosage forms, including tablets and capsules, creams and topicals, ointments, liquids and injectables. At present, SHMN has global licenses to manufacture more than 15 products and approximately 300 generic drugs and product formulations for distribution.
Recent SHMN News
- Shares of this BioPharma on a Tear as it Successfully Engineered a T-Cell From a Healthy Human Donor • AllPennyStocks.com • 06/10/2024 06:30:00 PM
- Gene Editing Company Joins Forces to Advance Gene Therapy • AllPennyStocks.com • 04/01/2024 03:46:00 PM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM